Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 1/20 | 0.31 |
| ▸ | BRAF | P15056 | 3/20 | 0.31 |
| ▸ | MRGPRX1 | Q96LB2 | 2/20 | 0.31 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.30 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.30 |
| ▸ | FEN1 | P39748 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7104848 | 0.75 | ADRA2A (0.33) | — | |
| SCHEMBL7098572 | 0.72 | ADRA1A (0.38) | — | |
| SCHEMBL7103288 | 0.67 | BRD4 (0.40) | KMOMRGPRX1PSIP1 | |
| SCHEMBL7248476 | 0.65 | BRAF (0.34) | BRAFMRGPRX1PSIP1 | |
| SCHEMBL7103403 | 0.65 | ADRA2A (0.33) | — | |
| SCHEMBL7097676 | 0.63 | ADRA2A (0.34) | BRAFMRGPRX1 | |
| SCHEMBL7248142 | 0.63 | MRGPRX1 (0.35) | BRAFMRGPRX1PSIP1ALOX5APFEN1 | |
| SCHEMBL27624078 | 0.62 | HPGD (0.36) | KMOPSIP1 | |
| SCHEMBL7105252 | 0.62 | HSD11B1 (0.36) | — | |
| SCHEMBL7097701 | 0.61 | ALDH1A1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030073850-A1 | 4-Imidazole derivatives of benzyl and restricted benzyl sulfonamides, sulfamides, ureas, carbamates, and amides and their use | ABBOTT LABORATORIES | 2003-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073850-A1 | 4-Imidazole derivatives of benzyl and restricted benzyl sulfonamides, sulfamides, ureas, carbamates, and amides and their use | ADRA1D, ADRB1, ADRA1A | KMO 2808/4885BRAF 2474/4885MRGPRX1 351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.